Electrophysiologic effects of salbutamol, a β2-selective agonist

被引:23
作者
Insulander, P [1 ]
Juhlin-Dannfelt, A
Freyschuss, U
Vallin, H
机构
[1] Huddinge Univ Hosp, Dept Cardiol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Dept Clin Physiol, S-14186 Huddinge, Sweden
[3] Karolinska Hosp, Dept Clin Physiol, Thorac Clin, S-10401 Stockholm, Sweden
关键词
salbutamol; dobutamine; beta(2)-agonist; electrophysiology; beta adrenoceptor;
D O I
10.1046/j.1540-8167.2004.03105.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Electrophysiologic Effects of Salbutamol. Introduction: A positive chronotropic effect of beta(2) stimulation is well known. Case reports of ventricular arrhythmias during beta(2)-inhalation therapy have been published. The aim of this study was to asses the overall electrophysiologic effects of the beta(2)-agonist salbutamol. Methods and Results: Ellectrophysiologic and hemodynamic variables were measured in 10 healthy volunteers during atrial pacing at baseline and during infusion of salbutamol at two different rates (0.1 and 0.2 mug/kg/min). To characterize beta(2)-agonist effects, a comparison was made with the beta(1)-selective agonist dobutamine. Salbutamol infusion produced significant changes in ellectrophysiologic properties in both myocardial and nodal tissues, with significantly greater effects on nodal properties. The proportional decreases in AV nodal parameters were more pronounced than in the sinus node (P < 0.001). An interesting result was a significant increase in the duration of the QS interval, which in the presence of an unchanged His-Purkinje conduction (HV) represents slower depolarization of the ventricle. QT dispersion also increased. Conclusion: Infusion of salbutamol results in significant ellectrophysiologic effects on most heart structures, proportionally most pronounced in the AV node. Discordant effects on ventricular conduction, which slowed, and the refractoriness of the ventricular myocardium, which shortened, were seen. QT dispersion was increased.
引用
收藏
页码:316 / 322
页数:7
相关论文
共 40 条
[21]   BARORECEPTOR CONTROL OF ATRIOVENTRICULAR-CONDUCTION IN MAN [J].
MANCIA, G ;
BONAZZI, O ;
POZZONI, L ;
FERRARI, A ;
GARDUMI, M ;
GREGORINI, L ;
PERONDI, R .
CIRCULATION RESEARCH, 1979, 44 (06) :752-758
[22]   DETRIMENTAL ARRHYTHMOGENIC AND SUSTAINED BENEFICIAL HEMODYNAMIC-EFFECTS OF ORAL SALBUTAMOL IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE [J].
METTAUER, B ;
ROULEAU, JL ;
BURGESS, JH .
AMERICAN HEART JOURNAL, 1985, 109 (04) :840-847
[23]   HEMODYNAMIC-EFFECTS OF SALBUTAMOL, AN ORAL LONG-ACTING BETA-STIMULANT, IN PATIENTS WITH CONGESTIVE HEART-FAILURE [J].
MIFUNE, J ;
KURAMOTO, K ;
UEDA, K ;
MATSUSHITA, S ;
KUWAJIMA, I ;
SAKAI, M ;
IWASAKI, T ;
MOROKI, N ;
MURAKAMI, M .
AMERICAN HEART JOURNAL, 1982, 104 (05) :1011-1015
[24]   ELECTROPHYSIOLOGIC EFFECTS OF EPINEPHRINE IN HUMANS [J].
MORADY, F ;
NELSON, SD ;
KOU, WH ;
PRATLEY, R ;
SCHMALTZ, S ;
DEBUITLEIR, M ;
HALTER, JB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (06) :1235-1244
[25]   METABOLIC AND CARDIOVASCULAR SIDE-EFFECTS OF THE BETA-2-ADRENOCEPTOR AGONISTS SALBUTAMOL AND RIMITEROL [J].
PHILLIPS, PJ ;
VEDIG, AE ;
JONES, PL ;
CHAPMAN, MG ;
COLLINS, M ;
EDWARDS, JB ;
SMEATON, TC ;
DUNCAN, BM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (05) :483-491
[26]  
ROBINSON C, 1978, BRIT HEART J, V40, P14
[27]   beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: Identification of a high beta(2)-adrenergic receptor density [J].
Rodefeld, MD ;
Beau, SL ;
Schuessler, RB ;
Boineau, JP ;
Saffitz, JE .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1996, 7 (11) :1039-1049
[28]   BENEFICIAL EFFECT OF SALBUTAMOL ON CARDIAC-FUNCTION IN SEVERE CONGESTIVE CARDIOMYOPATHY - EFFECT ON SYSTOLIC AND DIASTOLIC FUNCTION OF LEFT-VENTRICLE [J].
SHARMA, B ;
GOODWIN, JF .
CIRCULATION, 1978, 58 (03) :449-460
[29]  
SIMONSSON BG, 1972, ACTA MED SCAND, V192, P371
[30]   Increased survival with beta-blockers: Importance of ancillary properties [J].
Soriano, JB ;
Hoes, AW ;
Meems, L ;
Grobbee, DE .
PROGRESS IN CARDIOVASCULAR DISEASES, 1997, 39 (05) :445-456